Polymeric siRNA nanomedicine targeting BACE1 in APP/PS1 transgenic AD mouse model can efficiently penetrate the BBB via glycemia-controlled glucose transporter-1–mediated transport, ensuring that siRNAs decrease BACE1 expression. This evidence concerns the gene APP and Alzheimer disease.